Grape Cell Culture Mucosal Delivery for Inflammatory Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular diseases, particularly atherosclerosis, have limited success due to their focus on preventing plaque formation and inflammation, and the bioavailability of polyphenols from red wine and grape extracts is inconsistent and low, leading to ineffective therapeutic outcomes.
Innovation Solution
A pharmaceutical composition comprising a fruit cell culture or grape cell line culture, formulated for mucosal delivery, which enhances the bioavailability of anti-inflammatory agents like polyphenols, thereby reducing inflammatory markers and increasing anti-inflammatory markers in endothelial cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polyphenols from red wine and grape extracts are used as anti-inflammatory agents, then therapeutic effects are achieved, but bioavailability is inconsistent and low
Solution Approach 1:
The patent uses mucosal delivery systems (such as buccal or sublingual formulations) as intermediaries to transport polyphenols directly into the bloodstream through the mucous membranes, bypassing the gastrointestinal tract and liver metabolism that cause poor bioavailability. This mediator approach ensures consistent and reliable delivery of anti-inflammatory agents to the systemic circulation.
Solution Approach 2:
The patent changes the physical and chemical parameters of polyphenol delivery by using mucosal routes instead of oral ingestion, altering absorption kinetics, first-pass metabolism, and bioavailability. This parameter change transforms the unreliable oral delivery system into a consistent and effective therapeutic delivery method.
2Reliability
If traditional treatments focus on preventing plaque formation, then plaque development may be slowed, but inflammatory processes leading to plaque rupture are not adequately addressed
Solution Approach 1:
The patent applies preliminary anti-inflammatory action by delivering polyphenols through mucosal routes before inflammatory processes can lead to plaque rupture. This preliminary intervention stabilizes the endothelium and reduces inflammation proactively, preventing the harmful cascade that leads to thrombosis and cardiovascular events.
Solution Approach 2:
The patent converts the harmful inflammatory processes into a benefit by using polyphenols to modulate and redirect the inflammatory response. Instead of allowing uncontrolled inflammation to damage the vascular system, the treatment harnesses controlled anti-inflammatory action to stabilize plaques and prevent rupture, transforming a pathological process into a protective mechanism.
3Manufacturing precision
If current medical treatments are used, then plaque formation may be inhibited, but bioavailability and consistent therapeutic outcomes are not achieved
Solution Approach 1:
The patent introduces mucosal delivery systems as intermediaries that ensure precise and consistent delivery of polyphenols. This mediator system bypasses the variability of gastrointestinal absorption and hepatic metabolism, providing reliable and reproducible therapeutic concentrations of anti-inflammatory agents in the bloodstream.
Solution Approach 2:
The patent changes the delivery parameters from oral to mucosal administration, fundamentally altering the pharmacokinetic profile of polyphenols. This parameter change achieves consistent bioavailability and reliable therapeutic outcomes, eliminating the variability associated with traditional oral delivery methods.
Data Source
AI summary
Provided are methods of treating an inflammatory disorder in a subject, including administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition including a fruit, for example a grape, cell culture, cultured fruit cells, fruit cell culture extract, or cultured fruit cell extract, having an anti-inflammatory activity to treat the inflammatory disorder, wherein the inflammatory disorder is characterized by vascular endothelium dysfunction.